Allergy Therapeutics AGM to be held electronically on Tuesday 8th December 2020

Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, has announced that it has published the 2020 Annual report and accounts and the Notice of Annual General Meeting on the Company’s website at www.allergytherapeutics.com. Hard copies have been sent to shareholders who have requested this.

Allergy Therapeutics intends to hold its Annual General Meeting (AGM) electronically on Tuesday 8 December 2020, commencing at 2:00 p.m GMT. The AGM is an important event in the Company’s corporate calendar and usually provides an opportunity for the Company’s Directors to engage with shareholders. We remain committed to ensuring that shareholders can exercise their right to vote and ask questions at the upcoming AGM. However, in light of the compulsory government measures in force in response to the COVID-19 pandemic, and with the health and well-being of our colleagues, shareholders and the wider community in which we operate in mind, the AGM this year will be run as a virtual meeting in accordance with the provisions of the Corporate Insolvency and Governance Act 2020. Shareholders are therefore not able to attend the AGM in person. We will arrange for a quorum to be in place to transact the formal business of the AGM.

The Board is arranging a listen-only webinar facility to allow shareholders to attend the AGM and follow proceedings remotely. The webinar details will be published on the homepage of the Company’s website (www.allergytherapeutics.com) approximately 72 hours before the date and time of the meeting. The business of the AGM will be routine business only, which is required to be dealt with in order to ensure that the Company complies with the relevant legal requirements. As such shareholders should note that the meeting itself will deal only with proposing and voting on the Resolutions set out in the Notice. There will be no Board presentation or live Q&A session with the Board. Shareholders can submit questions for the Board in advance of the AGM by email to investor.relations@allergytherapeutics.com and the Board answer such questions at the Meeting.  

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn
Allergy therapeutics plc

More articles like this

Allergens dominate UK food recalls, finds study

More than half of food recalls in the United Kingdom over a 5-year period were due to allergens, according to a recently released study. Allergen-related recalls increased annually until 2019, peaking at 118 before decreasing to

Allergy Therapeutics welcomes new Non-Executive Directors

Allergy Therapeutics announced the appointments of Anthony Parker and Simon Shen to its Board as Non-Executive Directors effective immediately. “I would like to welcome Anthony and Simon. Southern Fox and ZQ Capital have been long-standing and supportive shareholders of Allergy

Allergy Therapeutics updates on its clinical programmes

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has announced that the first subject has been dosed in the pivotal Phase III G306 trial, to evaluate the efficacy and safety of

Allergy Therapeutics appoints two Non-Executive Directors

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has today announced the appointments of Anthony Parker and Zheqing (Simon) Shen as Non-Executive Directors of the Company, with immediate effect. Anthony represents

Allergies and Thanksgiving

As Thanksgiving and other holiday celebrations bring people around the table, Intermountain Healthcare dietitians say it’s crucial to take food allergies into consideration when planning the big meal. “A response to an allergic reaction can be

Allergy Therapeutics appoints Martin Hopcroft as interim CFO

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has announced the appointment of Martin Hopcroft to the role of Interim Chief Financial Officer (CFO). Martin will report into Chief Executive

Food business operator fined for allergy breach

A food business operator based in Newcastle, England has been fined in court after serving a dish containing peanuts to a woman with a peanut allergy, resulting in her being hospitalised. According to the Food Standards

Are restaurants taking allergies seriously?

In an engaging panel held at Twickenham Stadium as part of New Food’s Food Safety Conference 2022, experts came together to debate whether food allergy regulations in restaurants are sufficient. Here’s the highlights. Are restaurant allergy

Allergy Therapeutics Subscription to raise £7 million

Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical company specialising in allergy immunotherapy, today announces a conditional Subscription by the Subscribers, Southern Fox and ZQ Capital (acting through its affiliate SkyGem), to raise £7 million